Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 09 Apr, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Recent Articles
- 'Ghost Murmur' Used to Locate Downed Airman Was Trump's Bogus Reference to an Actual Technology
- House GOP Blocks Bid to Curtail Trump War Powers
- What Molecule Protects Your Brain, Fights Stress and Boosts Athletic Performance?
- Tesla Developing Smaller Cheaper EV
- Amazon Cloud Unit AI Revenue Exceeds $15 Billion on Annualized Basis
- List of Major AI Infrastructure Deals to Meet Booming Demand
- Mercedes Suffers Down Q1 on Plunging China Sales
- Intel and Google Expand Partnership to Address Demand for Versatile CPUs
- Chip Designer SiFive Raises $400 Million from Atreides, Nvidia to Step into Arm's Space
- Samsung Electronics Mulls Chip Testing and Packaging in Vietnam